Temozolomide (One Week On/One Week Off) versus radiation therapy in the first-line therapy of Anaplastic Astrocytoma and Glioblastoma in elderly patients: A Randomized, Phase III Study (Methysalem) [Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primartherapie Anaplastischer Astrozytome Und Glioblastome Bei alteren Patienten: Eine Randomisierte Phase III-Studie (Methusalem)]

Trial Profile

Temozolomide (One Week On/One Week Off) versus radiation therapy in the first-line therapy of Anaplastic Astrocytoma and Glioblastoma in elderly patients: A Randomized, Phase III Study (Methysalem) [Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primartherapie Anaplastischer Astrozytome Und Glioblastome Bei alteren Patienten: Eine Randomisierte Phase III-Studie (Methusalem)]

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma
  • Focus Biomarker; Therapeutic Use
  • Acronyms Methusalem
  • Most Recent Events

    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003684).
    • 29 Dec 2011 Additional lead trial centre and investigators (Michael Weller, Wolfgang Wick) identified as reported by ClinicalTrials.gov.
    • 29 Dec 2011 Actual initiation date (Jan 2005) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top